Treatment of acute myocardial infarction in hemophiliacs should follow general population guidelines after optimal substitution therapy, utilizing new-generation stents and potent P2Y12 inhibitors.
This review highlights that with optimal substitution therapy, hemophilia patients with AMI can be treated similarly to the general population, utilizing new-generation stents and short DAPT.
Advances in the treatment of hemophilia have made the life expectancy of hemophiliacs similar to that of the general population. Physicians have begun to face age-related diseases not previously encountered in individuals with hemophilia. Treatment of acute myocardial infarction (AMI) is particularly challenging because the therapeutic strategies influence both the patient’s thrombotic and hemorrhagic risk. As progress has been made in the treatment of AMI over the last decade, we performed an in-depth analysis of the available literature, highlighting the latest advances in the therapy of AMI in hemophiliacs. It is generally accepted that after the optimal substitution therapy has been provided, patients with hemophilia should be treated in the same way as those in the general population. New-generation stents that allow short dual antiplatelet therapy and potent P2Y12 receptor inhibitors have begun to be successfully used. At a time when specific recommendations and relevant data are scarce, our study provides up-to-date information to physicians involved in the treatment of AMI in hemophiliacs.
Bădescu et al. (Mon,) conducted a review in Acute myocardial infarction in patients with congenital hemophilia. Acute myocardial infarction therapy (new-generation stents, P2Y12 inhibitors) was evaluated. Treatment of acute myocardial infarction in hemophiliacs should follow general population guidelines after optimal substitution therapy, utilizing new-generation stents and potent P2Y12 inhibitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: